BIM Stock Overview
Develops and markets in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for BIM from our risk checks.
bioMérieux S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €97.50 |
| 52 Week High | €111.50 |
| 52 Week Low | €88.25 |
| Beta | 0.22 |
| 11 Month Change | -6.88% |
| 3 Month Change | -6.16% |
| 1 Year Change | 0.31% |
| 33 Year Change | -18.95% |
| 5 Year Change | 17.26% |
| Change since IPO | 875.00% |
Recent News & Updates
Is bioMérieux (EPA:BIM) Using Too Much Debt?
Nov 01
Is There An Opportunity With bioMérieux S.A.'s (EPA:BIM) 31% Undervaluation?
Oct 14bioMérieux S.A.'s (EPA:BIM) Popularity With Investors Is Under Threat From Overpricing
Sep 26bioMérieux S.A. (EPA:BIM) Just Reported Interim Earnings: Have Analysts Changed Their Mind On The Stock?
Sep 08Return Trends At bioMérieux (EPA:BIM) Aren't Appealing
Aug 03Recent updates
Is bioMérieux (EPA:BIM) Using Too Much Debt?
Nov 01Is There An Opportunity With bioMérieux S.A.'s (EPA:BIM) 31% Undervaluation?
Oct 14bioMérieux S.A.'s (EPA:BIM) Popularity With Investors Is Under Threat From Overpricing
Sep 26bioMérieux S.A. (EPA:BIM) Just Reported Interim Earnings: Have Analysts Changed Their Mind On The Stock?
Sep 08Return Trends At bioMérieux (EPA:BIM) Aren't Appealing
Aug 03bioMérieux S.A.'s (EPA:BIM) Price In Tune With Earnings
May 30Investors Met With Slowing Returns on Capital At bioMérieux (EPA:BIM)
Apr 18bioMérieux's (EPA:BIM) Conservative Accounting Might Explain Soft Earnings
Mar 31bioMérieux S.A. Just Missed Earnings - But Analysts Have Updated Their Models
Mar 17These 4 Measures Indicate That bioMérieux (EPA:BIM) Is Using Debt Reasonably Well
Mar 15bioMérieux S.A.'s (EPA:BIM) Price In Tune With Earnings
Jan 27bioMérieux (EPA:BIM) Has More To Do To Multiply In Value Going Forward
Jan 06A Look At The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)
Dec 16These 4 Measures Indicate That bioMérieux (EPA:BIM) Is Using Debt Reasonably Well
Oct 23bioMérieux (EPA:BIM) Has Some Way To Go To Become A Multi-Bagger
Oct 05There May Be Reason For Hope In bioMérieux's (EPA:BIM) Disappointing Earnings
Sep 15Estimating The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)
Sep 07Does bioMérieux (EPA:BIM) Have A Healthy Balance Sheet?
Jun 30Returns At bioMérieux (EPA:BIM) Appear To Be Weighed Down
Jun 09Is bioMérieux (EPA:BIM) Using Too Much Debt?
Mar 31The Return Trends At bioMérieux (EPA:BIM) Look Promising
Feb 23Do bioMérieux's (EPA:BIM) Earnings Warrant Your Attention?
Jan 27bioMérieux (EPA:BIM) Has A Pretty Healthy Balance Sheet
Dec 16bioMérieux (EPA:BIM) Ticks All The Boxes When It Comes To Earnings Growth
Oct 18Is bioMérieux (EPA:BIM) Using Too Much Debt?
Sep 14Investors Should Be Encouraged By bioMérieux's (EPA:BIM) Returns On Capital
Aug 11An Intrinsic Calculation For bioMérieux S.A. (EPA:BIM) Suggests It's 20% Undervalued
Jul 23Do bioMérieux's (EPA:BIM) Earnings Warrant Your Attention?
Jul 05bioMérieux's (EPA:BIM) Dividend Will Be Increased To €0.85
May 26Shareholders Would Enjoy A Repeat Of bioMérieux's (EPA:BIM) Recent Growth In Returns
May 11bioMérieux (EPA:BIM) Is Paying Out A Larger Dividend Than Last Year
Apr 23bioMérieux (EPA:BIM) Has Announced That It Will Be Increasing Its Dividend To €0.85
Apr 09bioMérieux's (EPA:BIM) Dividend Will Be Increased To €0.85
Mar 25Does bioMérieux (EPA:BIM) Have A Healthy Balance Sheet?
Mar 13I Ran A Stock Scan For Earnings Growth And bioMérieux (EPA:BIM) Passed With Ease
Feb 08Why We Like The Returns At bioMérieux (EPA:BIM)
Dec 21Calculating The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)
Dec 07Here's Why We Think bioMérieux (EPA:BIM) Is Well Worth Watching
Nov 07Is bioMérieux (EPA:BIM) A Risky Investment?
Oct 07Investors Shouldn't Overlook bioMérieux's (EPA:BIM) Impressive Returns On Capital
Sep 22Estimating The Fair Value Of bioMérieux S.A. (EPA:BIM)
Sep 07Here's Why I Think bioMérieux (EPA:BIM) Might Deserve Your Attention Today
Aug 06There's Been No Shortage Of Growth Recently For bioMérieux's (EPA:BIM) Returns On Capital
Jun 15A Look At The Fair Value Of bioMérieux S.A. (EPA:BIM)
May 31Here's Why I Think bioMérieux (EPA:BIM) Might Deserve Your Attention Today
Apr 30bioMérieux (EPA:BIM) Could Easily Take On More Debt
Mar 28The Trend Of High Returns At bioMérieux (EPA:BIM) Has Us Very Interested
Mar 13Calculating The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)
Feb 25If You Had Bought bioMérieux (EPA:BIM) Shares Five Years Ago You'd Have Earned 237% Returns
Feb 09If You Like EPS Growth Then Check Out bioMérieux (EPA:BIM) Before It's Too Late
Jan 20
Could The Market Be Wrong About bioMérieux S.A. (EPA:BIM) Given Its Attractive Financial Prospects?
Dec 30These 4 Measures Indicate That bioMérieux (EPA:BIM) Is Using Debt Reasonably Well
Dec 17Shareholder Returns
| BIM | FR Medical Equipment | FR Market | |
|---|---|---|---|
| 7D | -3.8% | 2.7% | -0.3% |
| 1Y | 0.3% | 26.7% | -3.5% |
Return vs Industry: BIM underperformed the French Medical Equipment industry which returned 28.4% over the past year.
Return vs Market: BIM exceeded the French Market which returned -2.5% over the past year.
Price Volatility
| BIM volatility | |
|---|---|
| BIM Average Weekly Movement | 3.4% |
| Medical Equipment Industry Average Movement | 5.4% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.2% |
| 10% least volatile stocks in FR Market | 2.2% |
Stable Share Price: BIM has not had significant price volatility in the past 3 months compared to the French market.
Volatility Over Time: BIM's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1963 | 13,696 | Pierre Boulud | www.biomerieux.com |
bioMérieux S.A. develops and markets in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers CHROMID RANGE, a chromogen culture media; RAPIDEC CARBA NP biochemical test for the detection of carbapenemaseproducing bacteria; air, surface, and water monitoring systems; BACT/ALERT VIRTUO BACT/ALERT 3D, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction (PCR) system; BIOFIRE SPOTFIRE Lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated Identification and antimicrobial susceptibility testing (AST) system; API RANGE standardized ID strips; VITEK REVEAL Rapid AST system; ETEST Gradient method on culture media; BIOMERIEUX EPISEQ CS whole genome sequencing solution for epidemiologic monitoring; and VIDASB·R·A·H·M·S PCTTM, a specific marker of severe bacterial infections/sepsis. It also provides Biomérieux vision suite, a software that provides actionable information to support diagnosis and clinical decision making; culture media and associated instruments; ARGENE Monoplex PCR tests; NUCLISENS ranges, a product for automation of the molecular biology laboratory and extraction; EMAG system For DNA and RNA extraction; ESTREAM, an automated preparation station for samples to process PCR tests; GENE-UP and VERIFLOW ranges for detection of microorganisms for the food industry.
bioMérieux S.A. Fundamentals Summary
| BIM fundamental statistics | |
|---|---|
| Market cap | €11.51b |
| Earnings (TTM) | €411.30m |
| Revenue (TTM) | €3.81b |
28.0x
P/E Ratio3.0x
P/S RatioIs BIM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIM income statement (TTM) | |
|---|---|
| Revenue | €3.81b |
| Cost of Revenue | €1.69b |
| Gross Profit | €2.12b |
| Other Expenses | €1.71b |
| Earnings | €411.30m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.49 |
| Gross Margin | 55.72% |
| Net Profit Margin | 10.81% |
| Debt/Equity Ratio | 10.1% |
How did BIM perform over the long term?
See historical performance and comparison